Actively Recruiting
A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity
Led by Innovent Biologics Technology Limited (Shanghai R&D Center) · Updated on 2026-04-08
104
Participants Needed
1
Research Sites
55 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI3032 in healthy participants and multiple ascending doses of IBI3032 in participants with overweight or obesity. It consists of 2 parts: Part A is a single ascending dose (SAD) study in healthy participants, and Part B is a multiple ascending dose (MAD) study in participants with overweight or obesity during the 4-week treatment period.
CONDITIONS
Official Title
A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18-65 years (inclusive) at the time of informed consent.
- Participants must understand the procedures and methods of this study.
- Participants must be willing to complete the study in strict accordance with the clinical study protocol.
- Participants must voluntarily sign the informed consent form.
You will not qualify if you...
- Suspected allergy to any component of the study drug or GLP-1 receptor agonists.
- Use of GLP-1 receptor agonists within 3 months prior to screening.
- History of diabetes.
- HbA1c greater than or equal to 6.5%.
- Fasting blood glucose less than 3.9 mmol/L or greater than or equal to 7.0 mmol/L at screening.
- Any clinically significant abnormalities in vital signs or laboratory tests as judged by the investigator at screening.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongshan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, China, 200030
Actively Recruiting
Research Team
D
Dee Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here